Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

REGISTER for free or LOG IN to view this content

Become a GOLD or PLATINUM member to access PowerPoint files, presentation audio, and video

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

We Recommend